Javara and Tryon Medical Partners have announced that they have formed a collaboration to offer industry-sponsored, outpatient clinical trials to Tryon Medical Partners’ patients.
“This partnership is a win-win for both our patients and doctors,” said Dr. Dale Owen, CEO of Tryon Medical Partners and a cardiologist with the practice. “Our patients will now have an opportunity to directly participate in advanced medical trials at no cost, and our doctors will be able to work closely with Javara’s medical professionals on the development of an array of innovative new drugs and interventions. It is also another significant milestone in Tryon’s rapid growth and development since we opened our first of eight clinics in the Charlotte region last September,” Owen added.
Javara’s Clinical Trial Navigators will be embedded within Tryon’s clinics in South Park and Uptown and work alongside Tryon’s doctors and medical staff. Javara and Tryon will initially conduct clinical trials in internal medicine, endocrinology and dermatology. The team expects initial trials to begin in September 2019, and to grow to have 35 to 45 clinical trials underway within the first 18 months.
“Javara is very pleased to be partnering with the Tryon Medical Partners team to incorporate clinical research into their care offerings to patients and we are eager to get started,” said Jennifer Byrne, CEO of Javara. “We have watched Dr. Owen and his fellow doctors with great interest since they formed an independent practice last year, and believe we have found the perfect partner to work with in the Charlotte region to better integrate clinical research as part of care options for patients.”
The trials are part of the testing required by the Federal Drug Administration before new drugs or devices are approved for broad use with patients.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.